- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in Breast Cancer: When, How, and What Challenges?
Authors
Keywords
-
Journal
Biomedicines
Volume 9, Issue 11, Pages 1687
Publisher
MDPI AG
Online
2021-11-15
DOI
10.3390/biomedicines9111687
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antibodies to watch in 2021
- (2021) Hélène Kaplon et al. mAbs
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
- (2021) Hope S. Rugo et al. JAMA Oncology
- Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer
- (2021) Vignesh Sivaganesh et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis
- (2021) Michal Sternschuss et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
- (2021) Michael L. Maitland et al. CLINICAL CANCER RESEARCH
- The role of immunotherapy in advanced renal cell carcinoma
- (2021) Ercília Rita Mondlane et al. International Braz J Urol
- Prevalence and mutational determinants of high tumor mutation burden in breast cancer
- (2020) R. Barroso-Sousa et al. ANNALS OF ONCOLOGY
- Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes
- (2020) Dinja T. Kruger et al. APMIS
- HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
- (2020) Atefeh Arab et al. ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
- Role of Innate and Adaptive Immunity in the Efficacy of anti-HER2 Monoclonal Antibodies for HER2-positive Breast Cancer
- (2020) Antonino Musolino et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
- (2020) Daixi Ren et al. Molecular Cancer
- The single-cell pathology landscape of breast cancer
- (2020) Hartland W. Jackson et al. NATURE
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer
- (2020) K.G.K. Deepak et al. PHARMACOLOGICAL RESEARCH
- Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate
- (2020) Hideo Takahashi et al. Scientific Reports
- Overcoming Endocrine Resistance in Breast Cancer
- (2020) Ariella B. Hanker et al. CANCER CELL
- High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas
- (2020) Ping Mei et al. Diagnostic Pathology
- Trastuzumab Deruxtecan: First Approval
- (2020) Susan J. Keam DRUGS
- Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
- (2020) Mauricio A. Medina et al. International Journal of Environmental Research and Public Health
- Breast cancer: Biology, biomarkers, and treatments
- (2020) Khadijeh Barzaman et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer
- (2020) J. A. Kyte et al. Journal of Translational Medicine
- Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
- (2020) Nicola Gaynor et al. SEMINARS IN CANCER BIOLOGY
- New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
- (2020) Essia Mezni et al. Cancers
- Mechanisms of Cancer Resistance to Immunotherapy
- (2020) Rilan Bai et al. Frontiers in Oncology
- Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges
- (2020) Debora de Melo Gagliato et al. BIODRUGS
- Systemic therapy for metastatic HER2-positive breast cancer
- (2020) Philip Bredin et al. SEMINARS IN ONCOLOGY
- Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
- (2020) Gayathri Nagaraj et al. ADVANCES IN THERAPY
- Immunotherapy for early breast cancer: too soon, too superficial, or just right?
- (2020) M.A. Franzoi et al. ANNALS OF ONCOLOGY
- Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
- (2020) Xupeng Bai et al. CANCER LETTERS
- Margetuximab for the treatment of HER2-positive metastatic breast cancer
- (2020) Paolo Tarantino et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
- (2020) Xiufang Xu et al. Molecular Cancer
- Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy
- (2020) Miguel Angel Galván Morales et al. MOLECULES
- Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
- (2020) Abirami Sivapiragasam et al. Cancer Medicine
- WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer
- (2019) Lorenzo Castagnoli et al. ONCOGENE
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial
- (2019) Sherene Loi et al. LANCET ONCOLOGY
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review
- (2019) Noam Pondé et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- Metabolic crosstalk in the breast cancer microenvironment
- (2019) Ana S. Dias et al. EUROPEAN JOURNAL OF CANCER
- Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
- (2019) E. Krasniqi et al. Journal of Hematology & Oncology
- Current status and limitations of immunotherapy for breast cancer
- (2019) Yoshihisa Tokumaru et al. SURGERY
- High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities
- (2019) Ioannis A. Voutsadakis Targeted Oncology
- Immunotherapy: A Challenge of Breast Cancer Treatment
- (2019) Marilina García-Aranda et al. Cancers
- Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
- (2019) Francis W. Hunter et al. BRITISH JOURNAL OF CANCER
- Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations
- (2019) Indrė Januškevičienė et al. LIFE SCIENCES
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies
- (2019) Constantin N. Baxevanis et al. SEMINARS IN CANCER BIOLOGY
- PI3K Inhibitors in Breast Cancer Therapy
- (2019) Haley Ellis et al. Current Oncology Reports
- Mechanisms of immune evasion in breast cancer
- (2018) Joshua P. Bates et al. BMC CANCER
- Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer
- (2018) Fangxuan Li et al. CANCER BIOLOGY & THERAPY
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2018) Hope S. Rugo et al. CLINICAL CANCER RESEARCH
- Mechanisms of Intrinsic Tumor Resistance to Immunotherapy
- (2018) John Rieth et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
- (2018) Shixiang Wang et al. ONCOGENE
- Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
- (2018) Juan C. Almagro et al. Frontiers in Immunology
- Recent Advances in the Treatment of Breast Cancer
- (2018) Christy W. S. Tong et al. Frontiers in Oncology
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Cancer immunoediting and resistance to T cell-based immunotherapy
- (2018) Jake S. O’Donnell et al. Nature Reviews Clinical Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
- (2017) Andrew M K Law et al. ENDOCRINE-RELATED CANCER
- Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer
- (2017) António Polónia et al. JOURNAL OF CLINICAL PATHOLOGY
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
- (2017) Sean P. Arlauckas et al. Science Translational Medicine
- Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
- (2017) Aura Muntasell et al. Frontiers in Immunology
- The role of immune system exhaustion on cancer cell escape and anti-tumor immune induction after irradiation
- (2016) Fernando Mendes et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
- (2016) George Plitas et al. IMMUNITY
- The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity
- (2016) Gábor Tóth et al. mAbs
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer
- (2016) A Musolino et al. PHARMACOGENOMICS JOURNAL
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer
- (2016) Gulidanna Shayan et al. OncoImmunology
- Regulation of Tumor Metastasis by Myeloid-Derived Suppressor Cells
- (2015) Thomas Condamine et al. Annual Review of Medicine
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Adaptive Immune Regulation of Mammary Postnatal Organogenesis
- (2015) Vicki Plaks et al. DEVELOPMENTAL CELL
- Metabolic reprogramming: the emerging concept and associated therapeutic strategies
- (2015) Go J. Yoshida JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors
- (2015) D. S. Thommen et al. Cancer Immunology Research
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape
- (2014) Deepak Mittal et al. CURRENT OPINION IN IMMUNOLOGY
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Mammary Gland Involution as an Immunotherapeutic Target for Postpartum Breast Cancer
- (2014) Jaime Fornetti et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DRlo/neg Cells): The Gateway to Improved Responses
- (2014) Rebecca R. Laborde et al. Frontiers in Immunology
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Neoplastic and Stromal Cells Contribute to an Extracellular Matrix Gene Expression Profile Defining a Breast Cancer Subtype Likely to Progress
- (2013) Tiziana Triulzi et al. PLoS One
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 Is a Direct Target of Wnt/β-Catenin Signaling and Is Expressed in Human Melanoma Tumors
- (2008) Kavita V. Shah et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started